Objective: Successful biologic disease-modifying anti-rheumatic drug (bDMARD) dose reduction appears increasingly possible from clinical trials. The present study aimed to understand the patient perspective of bDMARD dose reduction.
target the drivers of inflammation, have proved of great value in inflammatory arthritis over the last 15 years (Nam et al., 2010) . For many patients resistant to previous medications, there have been dramatic improvements or even remission. In the UK, the National Institute for Health and Care Excellence (NICE) guidelines determine how and when bDMARDs should be started (NICE, 2010a (NICE, ,b, 2016a : intolerance/inefficacy of DMARDs, plus sustained inflammatory activity (e.g. disease activity score) (Van der Heijde, van't Hof, van Riel, & van de Putte, 1993) .
However, the long-term side effects of biologic therapies, including local reactions, increased risk of infection and potential malignancy, remain unknown (Holroyd et al., 2018) . Furthermore, these agents are expensive compared with conventional synthetic DMARDs (csDMARDs) (approximately £9,000/year versus oral methotrexate at £40/year). Therefore, to avoid unnecessary patient risk and National Health Service (NHS) costs, dose reduction is being investigated.
There is increasing evidence from randomized controlled trials that, once stable, some inflammatory arthritis patients can reduce the dose of bDMARDs without a significant increase in disease activity or reduction in quality of life (Fong et al., 2016; Henaux et al., 2018; Navarro-Compán et al., 2016; van Herwaarden et al., 2014; Závada et al., 2016) . However, some patients experience disease flares, requiring re-escalation of bDMARDs (Edwards, Fautrel, SchulzeKoops, Huizinga, & Kruger, 2017) . Most of the dose reduction data arise from randomized controlled trials in which patients have been randomized to predetermined dose reduction regimens (Ibrahim et al., 2017) . Little is known about dose reduction in clinical practice, where the reduction regimen could be individually tailored by dose and length of time over which reductions take place.
In clinical practice, patients and clinicians must reach collaborative decisions if patients are to attempt dose reduction and adhere to that reduction. In a bDMARD dose reduction trial, 32-56% of patients declined to participate (Marsman et al., 2015) . Some declined because it was research, and others because of anxiety about dose reduction. If bDMARD dose reduction is to be introduced successfully as routine clinical practice, it is therefore necessary to understand patients' perceptions and concerns about it, in order to guide clinic discussions and support informed decision making. The aim of the present study was to obtain a greater understanding of the patient perspective of bDMARD dose reduction.
| METHODS

Research ethics committee approval was obtained (West of Scotland
Research Ethics Service, 17/WS/0014) and patients provided written, informed consent. Patients with confirmed RA, AS or PsA who were self-administering subcutaneous bDMARD therapy at two NHS trusts were invited to participate in semi-structured interviews. They were either approached by a research nurse during a clinic visit or mailed an invitation using a departmental database. In one trust, rheumatologists were collaborating with stable patients to reduce their biologics by increasing the interval between doses using a flexible and individualized approach (Biologics Treatment Reduction by Interval Management [B-TRIM] ). To capture a broad range of experiences, patients were purposefully sampled to reflect a range of characteristics that might potentially influence their views (Ritchie & Lewis, 2003) . Purposeful sampling was facilitated by maintaining a spreadsheet detailing age, gender, diagnosis, disease duration and currently reducing/not reducing biologics for each patient as they were recruited, so that toward the end of recruitment we could "purposefully" select patients to address any under-represented characteristics. To include the perspectives of patients at different stages of treatment, patients were recruited either near the start of therapy (3-12 months) or ≥12 months later and in stable remission/low disease activity for ≥6 months (Disease Activity Score in 28 joints <3.2 in RA; <3 tender and <3 swollen joints in PsA; Bath Ankylosing Spondylitis Disease Activity Index score <4 in AS) (Garrett et al., 1994) . It was intended to recruit 15-20 patients, by which point most major themes were likely to have been captured (data saturation) (Guest, Bunce, & Johnson, 2006 ).
Prior to interview, participants completed a perceived disease activity visual analogue score (scored 0-10, from not active to very active), Health Assessment Questionnaire for disability (Fries, Spitz, What do/did you think the outcome of dose reduction might be?
What information could/did your clinician provide to help you make a decision on dose reduction?
Would/do you feel confident in being able to monitor your own progress and change your medications to suit how you feel?
Additional questions for patients who had tried to reduce biologics:
Was there any information that would have been useful that you did not receive?
What information would you give to other patients thinking of reducing their dose?
Did you feel involved and in control of the decision-making process?
What do you think of the patient record form for dose reduction?
TNF, tumour necrosis factor Kraines, & Holman, 1980) and Rheumatoid Arthritis Impact of Disease (RAID) Scale for quality of life (Gossec et al., 2011) . The RAID comprises seven numerical rating scales covering perceived physical symptoms, emotional impact and coping with RA, with a weighted algorithm giving a total score of 0-10, where 10 is the worst outcome.
One-to-one interviews were conducted (by A.H.-F.) in local hospitals or at home, using an interview schedule of neutral, open-ended questions (Table 1) explored for links. A subset was independently analysed by team members S.Ha., and S.F., followed by a full team discussion of combined findings. Based on these discussions the final themes and subthemes were refined (by S.Hew.). Analysis was iterative, moving back and forth between transcripts, and concurrent with data collection, so that emerging themes could be explored in later interviews. No new major themes arose by interview 15, suggesting that data saturation had been reached (Guest et al., 2006) .
| RESULTS
A total of 38 patients were invited to take part, 18 of whom expressed interest and 15 attended for interview, with interviews lasting approximately 30-60 min. Patients included 10 female patients, with an age range of 31-77 years, with 5-40 years' disease duration (Table 2) . These five themes encapsulated 14 subthemes. The question of bDMARD dose reduction engendered reflection on life both before and after bDMARDs ("Where I was then"; "Where I am now"), with patients raising both concerns about reduction ("Fears for the future") and potential benefits ("Hopes for the future"), highlighting questions that they wanted to be addressed ("Information needs").
| Theme 1: Where I was then
When bDMARD dose reduction was discussed, patients reflected on their life beforehand.
| Disease and life out of control
Uncontrolled disease activity before biologics was recalled as overwhelming, with all-consuming pain, loss of function, depression and a sense that life was out of control:
A "cocoon of pain" because that's all that's around you. Health Assessment Questionnaire 0-3 (3 = severe disability).
b Rheumatoid Arthritis Impact of Disease 0-10 (10 -severe impact). 
| Long journey to biologics
Many felt that the process of accessing bDMARDs was long, and that they had to "qualify" in order to receive them:
It was quite difficult to actually get onto the drug. There 
| Miracle drug
For many patients, these improvements were dramatic and lifechanging:
It has been a bit of a miracle drug for me, really. 
| DISCUSSION
The present study highlighted the fact that patients have significant concerns that bDMARD dose reduction would risk losing their current disease control, many assuming it to be a cost-saving exercise. By contrast, they often simultaneously held positive views regarding fewer side effects, fewer restrictions and better use of NHS resources. Most weighed these in the balance during the interview and, in so doing, highlighted the issues they wanted to be addressed during clinic discussions, better to inform their decision making. Crucially, they wanted to understand the rationale for a dose reduction for them, personally. They also wanted to hear other patients' experiences, either included in a dose reduction leaflet or as a face-to-face group education session.
Whereas most patients hoped for a reduction in the risk of side effects and were willing (hypothetically) to try a dose reduction, two of the 15 patients were not prepared even to consider a reduction if it was offered, as they felt that this would have been an exercise to save the NHS money, and not in their personal interests. By contrast, three patients had initiated a dose reduction themselves, before informing their rheumatology team. A limitation of the present study was that none of the patients interviewed had been offered a dose reduction clinically and declined it, or tried and failed, which might have broadened the findings. Although one of the strengths of the study was that a subset of transcripts was analysed by a patient partner (S.F.), a limitation was that no one external to the research team examined any transcripts.
In the early days of bDMARD therapy, the possibility of remission and a subsequent reduction or discontinuation of therapy was not envisaged, and patients in two early qualitative studies expressed great fear that their bDMARD might one day be discontinued, and that they would lose the transformation that these agents had brought about (Marshall, Wilson, Lapworth, & Kay, 2004; Sanderson, Calnan, Morris, Richards, & Hewlett, 2009 ). In the present study, patients had similar concerns, and also worried that if bDMARDs needed to be re-escalated, they might not be as effective. Furthermore, patients worried that they might have to "qualify' again", repeating the previous long journey for access. Therefore, patients' suggestions that the possibility of a future dose reduction should be included in information leaflets at bDMARD initiation would be helpful.
Interestingly, many patients cited losing the restrictions of bDMARDs as a possible positive effect of a dose reduction, particularly the need to make arrangements to stay at home for drug deliveries and for managing drugs when abroad. It is possible that the transformative effects of bDMARDs mean that they are now working and taking holidays abroad, thus generating these previously unencountered complexities of managing medications to fit with their more active lifestyle.
These data suggest that there is a need for clear information on the rationale for biologic dose reduction and for an opportunity for patients to discuss their positive and negative thoughts with the clinician. A leaflet has therefore been produced, with the help of the patients on the study team, and is being piloted as the basis for clinic discussions. Patients wanted to understand other patients' dose reduction experiences, and it is possible that a decision aid might help them to weigh up what is important to them (Stacey et al., 2017) . A clear rationale, open discussion, collaborative decisions, support from and easy access to the team, the ability to decide on their own reduction programme and flexibility to increase bDMARDs again, along with a sense of control, appear to be key factors in decision making.
